CSBio CSBio

X
[{"orgOrder":0,"company":"Adcendo","sponsor":"Novo Seeds","pharmaFlowCategory":"D","amount":"$62.2 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Seeds Co-leads Adcendo's EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Adcendo"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The new financing, which is the largest Series A financing for a Danish biotech company to develop Antibody drug conjugate, will be used to establish a pipeline of ADCs directed at novel cancer targets and to bring the lead program targeting uPARAP/Endo180.

            Lead Product(s): Antibody drug conjugate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Novo Seeds

            Deal Size: $62.2 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing April 29, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY